Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA7 | P43166 | 3/20 | 0.49 |
| ▸ | CA6 | P23280 | 2/20 | 0.49 |
| ▸ | CA5A | P35218 | 2/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Toluenesulfonamide SCHEMBL5528880 | 1.00 | CA2 (0.49) | CA2CA9CA12CA1CA7 | |
| P-Toluenesulfonamide SCHEMBL5525016 | 1.00 | CA2 (0.49) | CA2CA9CA12CA1CA7 | |
| SCHEMBL5528701 | 0.82 | MEN1 (0.40) | AKR1B1KIF11 | |
| SCHEMBL5622851 | 0.82 | MEN1 (0.40) | AKR1B1KIF11 | |
| SCHEMBL5526501 | 0.82 | MEN1 (0.40) | AKR1B1KIF11 | |
| SCHEMBL788818 | 0.79 | KDM1A (0.50) | — | |
| SCHEMBL30664080 | 0.79 | KDM1A (0.50) | — | |
| SCHEMBL2147836 | 0.79 | KDM1A (0.50) | — | |
| SCHEMBL30316454 | 0.79 | KDM1A (0.50) | — | |
| SCHEMBL29529186 | 0.79 | KDM1A (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293682-A1 | Methods of Preparing Sulfinamides and Sulfoxides | APSINTERM, LLC | 2007-12-20 | — | — | US | disclosed |
| US-7256297-B2 | Methods of preparing sulfinamides and sulfoxides | APSINTERM, LLC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7064214-B2 | Methods of preparing sulfinamides and sulfoxides | APSINTERM LLC (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060128767-A1 | Methods of preparing sulfinamides and sulfoxides | SENANAYAKE CHRIS H | 2006-06-15 | — | — | US | disclosed |
| EP-1389184-A2 | METHODS OF PREPARING SULFINAMIDE AND SULFOXIDES | Apsinterm, LLC. (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030083517-A1 | Methods of preparing sulfinamides and sulfoxides | APSINTERM LLC | 2003-05-01 | — | — | US | disclosed |
| WO-2002083608-A2 | METHODS OF PREPARING SULFINAMIDE AND SULFOXIDES | APSINTERM LLC (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128767-A1 | Methods of preparing sulfinamides and sulfoxides | STS, TST, CBS | CA2 3428/4885CA9 2159/4885CA12 1775/4885 |
| US-20070293682-A1 | Methods of Preparing Sulfinamides and Sulfoxides | STS, TST, CBS | CA2 3428/4885CA9 2159/4885CA12 1775/4885 |
| US-20030083517-A1 | Methods of preparing sulfinamides and sulfoxides | STS, TST, CBS | CA2 3428/4885CA9 2159/4885CA12 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.